Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Michael Scordo, MD, Gunjan L. Shah, MDMS, Satyajit Kosuri, MD, Diego Adrianzen Herrera, MD, Sean Devlin, PhD, Molly A. Maloy, MS, Jimmy Nieves, RN, Taylor Borrill, CCRP, Scott T. Avecilla, MD PhD, Richard C. Meagher, PhD, Richard J. O'Reilly, MD, Guenther Koehne, MD PhD, Boglarka Gyurkocza, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD, Miguel Perales, MD, Sergio A. Giralt, MD, Brian C. Shaffer, MD

Blood (2016) 128 (22): 4621.

https://doi.org/10.1182/blood.V128.22.4621.4621

Published: 2016

Journal Articles

Outcomes of Rituximab for EBV Viremia/Post-Transplant Lymphoproliferative Disease in CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Kristen Poppiti, PharmD, Andrew Lin, PharmD, Nelly G. Adel, PharmD, BCOP, BCPS, Patrick Hilden, MS, Hugo Castro-Malaspina, MD

Blood (2016) 128 (22): 4623.

https://doi.org/10.1182/blood.V128.22.4623.4623

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Patients with Myelodysplastic Syndromes

Bartlomiej Getta, MBBS,, Ashwin Kishtagari, MD, Patrick Hilden, MS, Sean Devlin, PhD, Molly A. Maloy, MS, Patrick K. Gonzales, Brian C. Shaffer, MD, Doris M Ponce, MD, Boglarka Gyurkocza, MD, Juliet N. Barker, MBBS, Esperanza B. Papadopoulos, MD, Hugo Castro-Malaspina, MD, Ann A. Jakubowski, MD PhD, James W. Young, MD, Martin S. Tallman, MD, Miguel-Angel Perales, MD, Sergio A. Giralt, MD, Roni Tamari, MD, Virginia M. Klimek, MD

Blood (2016) 128 (22): 3188.

https://doi.org/10.1182/blood.V128.22.3188.3188

Published: 2016

Journal Articles

Prognostic Factors of CLL Patients Undergoing Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in the Immunochemotherapy Era

Oscar B. Lahoud, MD, Patrick Hilden, MS, Molly A. Maloy, MS, Parastoo B. Dahi, MD, Hugo Castro-Malaspina, MD, Miguel-Angel Perales, MD, Sergio A. Giralt, MD, Craig S. Sauter, MD

Blood (2016) 128 (22): 5865.

https://doi.org/10.1182/blood.V128.22.5865.5865

Published: 2016

Journal Articles

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Blood (2016) 128 (22): 5109.

https://doi.org/10.1182/blood.V128.22.5109.5109

Published: 2016

Journal Articles

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Raajit K. Rampal, MD, PhD, Roni Tamari, MD, Nan Zhang, MS, Caroline Jane McNamara, MBBS, Franck Rapaport, PhD, Rivka Litvin, Molly A. Maloy, MS, Hugo Castro-Malaspina, MD, Sergio Giralt, MD, Rona Singer Weinberg, PhD, John Mascarenhas, MD, Ruben A. Mesa, MD, Damiano Rondelli, MD, Amylou C. Dueck, PhD, Ross L. Levine, MD, Vikas Gupta, MD FRCP, FRCPath, Ronald Hoffman, MD

Blood (2016) 128 (22): 2301.

https://doi.org/10.1182/blood.V128.22.2301.2301

Published: 2016

Journal Articles

Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation

Kristen Beyer, PharmD, Anthony Proli, PharmD, Junting Zheng, Sean Devlin, PhD, Valkal Bhatt, PharmD, Andrew Lin, PharmD, Esperanza B. Papadopoulos, MD, Ann A. Jakubowski, MD PhD, Miguel Perales, MD, Sergio Giralt, MD, Hugo Castro-Malaspina, MD, Roni Tamari, MD

Blood (2016) 128 (22): 3392.

https://doi.org/10.1182/blood.V128.22.3392.3392

Published: 2016

Journal Articles

Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies

Blood (2015) 126 (23): 3231.

https://doi.org/10.1182/blood.V126.23.3231.3231

Published: 2015

Journal Articles

Second Allogeneic Stem Cell Transplantation for Hematologic Malignancies Using Chemotherapy Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa

Barbara Spitzer, MD, Miguel-Angel Perales, MD, Nancy A. Kernan, MD, Susan E. Prockop, MD, Nicholas Webb, Hugo Castro-Malaspina, MD, Esperanza B Papadopoulos, MD, James W. Young, MD, Andromachi Scaradavou, MD, Rachel Kobos, MD, Sergio Giralt, MD, Richard J O'Reilly, MD, Farid Boulad, MD

Blood (2014) 124 (21): 3942.

https://doi.org/10.1182/blood.V124.21.3942.3942

Published: 2014

Journal Articles

Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome

Blood (2014) 124 (21): 3903.

https://doi.org/10.1182/blood.V124.21.3903.3903

Published: 2014

Journal Articles

Allogeneic Transplantation for Chronic Myelomonocytic Leukemia (CMML) Is Associated with High Disease-Free Survival Even in the Setting of High-Risk Disease

Matias Eugenio Sanchez, MD, Kamal Kant Singh Abbi, MBBS, Roni Tamari, MD, Ann Jakubowsky, MD PhD, Esperanza B Papadopoulos, MD, Sean M. Devlin, PhD, Weiji Shi, MS, Craig S. Sauter, MD, Juliet N. Barker, MBBS(Hons), FRACP, Farid Boulad, MD, Sergio Giralt, MD, Richard Meagher, MD, Hugo Castro-Malaspina, MD

Blood (2014) 124 (21): 2575.

https://doi.org/10.1182/blood.V124.21.2575.2575

Published: 2014

Journal Articles

Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC

Roni Tamari, MD, Betul Oran, MD, Patrick Hilden, MS, Esperanza B Papadopoulos, MD, Piyanuch Kongtim, MD, Gabriela Rondon, MD, Ann A. Jakubowski, MD PhD, Borje S Andersson, MD PhD, Sean M. Devlin, PhD, Sairah Ahmed, MD, James W. Young, MD, Uday R. Popat, MD, Julianne Chen, Marcos de Lima, MD, Richard J O'Reilly, MD, Sergio Giralt, MD, Richard E. Champlin, Hugo Castro-Malaspina, MD

Blood (2014) 124 (21): 2546.

https://doi.org/10.1182/blood.V124.21.2546.2546

Published: 2014

Journal Articles

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

Izaskun Ceberio, MD, Patrick Hilden, MS, Sean M. Devlin, PhD, Molly Maloy, MA, Jenna D Goldberg, MD, Miguel A Perales, MD, Juliet N Barker, MBBS, (Hons), FRACP, Hugo Castro-Malaspina, MD, Guenther Koehne, MD, PhD, Doris M Ponce, MD, Craig S. Sauter, MD, Marcel R.M. van den Brink, MD, PhD, James W. Young, MD, Richard J. O'Reilly, MD, Sergio Giralt, MD, Ann A. Jakubowski, MD, PhD, Esperanza B Papadopoulos, M.D.

Blood (2013) 122 (21): 3387.

https://doi.org/10.1182/blood.V122.21.3387.3387

Published: 2013

Journal Articles

Adverse Cytogenetic Abnormalities At Diagnosis Are The Most Important Predictor Of Relapse Post T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Advanced Myelodysplastic Syndrome (MDS)

Roni Tamari, MD, Ann A. Jakubowski, MD, PhD, Esperanza B. Papadopoulos, MD, Sergio A Giralt, MD, Jenna D Goldberg, MD, Doris M Ponce, MD, Craig S. Sauter, MD, Patrick Hilden, MS, Sean Devlin, PhD, James W. Young, MD, Hugo Castro-Malaspina, MD

Blood (2013) 122 (21): 3379.

https://doi.org/10.1182/blood.V122.21.3379.3379

Published: 2013

Journal Articles

The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS

Ravin Ratan, MD, Izaskun Ceberio, MD, Patrick Hilden, MS, Sean M. Devlin, PhD, Molly A Malloy, Juliet N Barker, MBBS, (Hons), FRACP, Hugo Castro-Malaspina, MD, Ann A. Jakubowski, MD, PhD, Guenther Koehne, MD, PhD, Esperanza B Papadopoulos, MD, Doris M Ponce, MD, Craig S. Sauter, MD, Marcel R.M. van den Brink, MD, PhD, James W. Young, MD, Richard J. O'Reilly, MD, Sergio Giralt, MD, Jenna D Goldberg, MD, Miguel-Angel Perales, MD

Blood (2013) 122 (21): 2045.

https://doi.org/10.1182/blood.V122.21.2045.2045

Published: 2013

Journal Articles

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

Juliet N Barker, MBBS, (Hons), FRACP, Doris M Ponce, MD, Parastoo B Dahi, MD, Sean Devlin, PhD, Katherine L Evans, BA, Marissa N Lubin, BA, Richard Meagher, PhD, Lilian Reich, MD, Hugo Castro-Malaspina, MD, Jenna D Goldberg, MD, Ann A. Jakubowski, MD, PhD, Guenther Koehne, MD, PhD, Esperanza B Papadopoulos, M.D., Miguel-Angel Perales, MD, Craig S. Sauter, MD, Andromachi Scaradavou, MD, Nancy A. Kernan, MD, Sergio A Giralt, MD, Richard J. O'Reilly, MD

Blood (2013) 122 (21): 298.

https://doi.org/10.1182/blood.V122.21.298.298

Published: 2013

Journal Articles

Pre-Transplant FDG-PET Scan Lacks Prognostic Value in Chemosensitive B-Cell Non-Hodgkin Lymphoma Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation.

Craig S. Sauter, MD, Hugo Castro-Malaspina, MD, Michael Scordo, MD, Lauren Lechner, Wayne Cohen-Levy, Miguel-Angel Perales, MD, Jenna D Goldberg, MD, Sergio Giralt, MD, Juliet N Barker, MBBS, (Hons), FRACP, Craig H. Moskowitz, MD

Blood (2012) 120 (21): 3130.

https://doi.org/10.1182/blood.V120.21.3130.3130

Published: 2012

Journal Articles

Remission Duration ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose Therapy and Autologous Stem Cell Rescue.

Matthew A Lunning, DO, Jocelyn C Maragulia, Craig H. Moskowitz, MD, Matthew J. Matasar, MD, MS, Hugo Castro-Malaspina, MD, Sergio Giralt, MD, Andrew D. Zelenetz, MD, PhD, Craig S. Sauter, MD

Blood (2012) 120 (21): 3136.

https://doi.org/10.1182/blood.V120.21.3136.3136

Published: 2012

Journal Articles

Bone Marrow Mixed Chimerism Is a Risk Factor for Relapse After T-Cell Depleted Allogeneic Stem Cell Transplant

Amanda L Olson, MD, Juliet N Barker, MBBS, (Hons), FRACP, Hugo Castro-Malaspina, MD, Sean Devlin, PhD, Sergio A Giralt, MD, Jenna D Goldberg, MD, Rachel Lehrman, BA, Molly Maloy, BA, Richard J. O'Reilly, MD, Miguel-Angel Perales, MD, Esperanza B. Papadopoulos, MD, Ann A Jakubowski, MD, PhD

Blood (2012) 120 (21): 4145.

https://doi.org/10.1182/blood.V120.21.4145.4145

Published: 2012

Journal Articles

Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd

Ceberio Izaskun, Sean Devlin, PhD, Craig S. Sauter, MD, Juliet N Barker, MBBS, (Hons), FRACP, Hugo Castro-Malaspina, MD, Sergio A Giralt, MD, Doris M Ponce, MD, Lauren Lechner, Anne Marie R Gonzales, Jenna D Goldberg, MD, Miguel-Angel Perales, MD

Blood (2012) 120 (21): 4194.

https://doi.org/10.1182/blood.V120.21.4194.4194

Published: 2012

NARROW

A Comprehensive Analysis of Late Toxicities and Associated Risk Factors in Long-Term Survivors of Myeloablative Conditioned Allogeneic Hematopoietic Cell Transplantation Using Ex-Vivo CD34+ Selection-Based Graft-Versus-Host Disease Prophylaxis

Outcomes of Rituximab for EBV Viremia/Post-Transplant Lymphoproliferative Disease in CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic Hematopoietic Stem Cell Transplantation Is Underutilized in Patients with Myelodysplastic Syndromes

Prognostic Factors of CLL Patients Undergoing Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation in the Immunochemotherapy Era

Clinical Relevant Alterations Identified By Comprehensive Genomic Profiling Can Potentially Improve Therapeutic Option and Change Prognosis in Hematologic Malignancies

Impact of Genomic Alterations on Outcomes in Myelofibrosis Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Outcomes of Pharmacokinetically Targeted Busulfan-Based Conditioning Regimen for Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia Undergoing CD34 Selected Allogeneic Hematopoietic Stem Cell Transplantation

Age-Adjusted Co-Morbidity Score - but Not Revised Disease Risk Index - Is Associated with Progression-Free Survival after Intermediate Intensity Double Unit CBT in Adults with Hematologic Malignancies

Second Allogeneic Stem Cell Transplantation for Hematologic Malignancies Using Chemotherapy Only Cytoreduction with Clofarabine, Melphalan, and Thiotepa

Double-Unit Cord Blood (CB) Transplantation (DCBT) Combined with Haplo-Identical CD34+ Selected Peripheral Blood Stem Cells (PBSC) Is Associated with Enhanced Neutrophil Recovery, Universal Haplo Rejection and Frequent Pre-Engraftment Syndrome

Allogeneic Transplantation for Chronic Myelomonocytic Leukemia (CMML) Is Associated with High Disease-Free Survival Even in the Setting of High-Risk Disease

Allo- HSCT for Advanced Myelodysplastic Syndrome:MSKCC Vs MDACC

T-Cell Depleted (TCD) Hematopoietic Stem Cell Transplantation (HCT) For Adult Patients With Acute Myelogenous Leukemia (AML) In First and Second Remission: Long-Term Disease Free Survival(DFS) With a Significantly Reduced Risk Of Graft-Versus-Host Disease(GvHD)

Adverse Cytogenetic Abnormalities At Diagnosis Are The Most Important Predictor Of Relapse Post T Cell Depleted (TCD) Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Advanced Myelodysplastic Syndrome (MDS)

The Hematopoietic Cell Transplant-Co-Morbidity Index (HCT-CI) Predicts Outcomes After T Cell Depleted (TCD) Allogeneic HCT For AML and MDS

Double-Unit Cord Blood (CB) Transplantation Combined With Haplo-Identical CD34+ Cell-Selected PBSC Results In 100% CB Engraftment With Enhanced Myeloid Recovery

Pre-Transplant FDG-PET Scan Lacks Prognostic Value in Chemosensitive B-Cell Non-Hodgkin Lymphoma Patients Undergoing Non-Myeloablative Allogeneic Stem Cell Transplantation.

Remission Duration ≤ 12 Months for Early Relapsed and Refractory Follicular Lymphoma Is Predictive of Early Failures Post-High Dose Therapy and Autologous Stem Cell Rescue.

Bone Marrow Mixed Chimerism Is a Risk Factor for Relapse After T-Cell Depleted Allogeneic Stem Cell Transplant

Sirolimus, Tacrolimus and Low-Dose Methotrexate Based Graft-Versus-Host Disease (GVHD) Prophylaxis After Non-Ablative or Reduced Intensity Conditioning in Related and Unrelated Donor Allogeneic Stem Cell Transplantation: Decreased Severe Early aGVHD but Persistence of Late Acute Gvhd

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only